Immuneering Corporation filings document the disclosure record of a late-stage clinical oncology company developing Deep Cyclic Inhibitors for cancer. Recent Form 8-K reports cover operating and financial results, R&D spending, capital resources, and clinical updates for atebimetinib (IMM-1-104), including its evaluation with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer.
Proxy materials describe annual meeting matters for holders of Class A common stock, including director elections, auditor ratification, board governance and voting procedures. The filing record also includes material-event disclosures addressing material agreements, capital-structure matters, shareholder votes, and regulatory and clinical disclosures for the company’s oncology development programs.
Immuneering Corporation announced its financial results for the quarter ended September 30, 2025 and shared operational updates. The details are contained in a press release dated November 12, 2025, which is provided as an exhibit and treated as furnished rather than filed under securities laws.
FMR LLC and Abigail P. Johnson reported beneficial ownership of 8,787,052 shares of Immuneering Corp Class A common stock, representing 14.5% of the class as of 09/30/2025. The filing shows FMR LLC holds 8,780,283 shares with sole voting power and 8,787,052 shares with sole dispositive power, while Abigail P. Johnson is reported with sole dispositive power for the same 8,787,052 shares.
The filing discloses that the Fidelity Growth Company Commingled Pool held 3,317,460 shares, or 5.5% of the class, at the same date. Signatures attest the holdings were acquired in the ordinary course of business and not for the purpose of changing control.
Insider purchase by Director Peter Feinberg. The filing shows a purchase of 7,500 shares of Class A common stock on 10/03/2025 at a reported price of $6.67 per share. After the transaction, Mr. Feinberg directly owns 156,766 shares and indirectly beneficially owns larger stakes through entities: 392,242, 476,615, and 115,441 shares via three general‑partner relationships, bringing total reported beneficial holdings across direct and indirect positions to a material position in the company.
HBM Healthcare Investments (Cayman) Ltd. filed a Schedule 13G reporting beneficial ownership of 3,646,304 shares of Immuneering Corp Class A common stock, representing approximately 5.7% of the 63,483,397 shares outstanding as of September 30, 2025. The filing states the shares were not acquired to change or influence control of the company and that voting and investment power is exercised by HBM's board.
The reporting person is organized in the Cayman Islands and lists sole voting and dispositive power over all reported shares. The statement includes a signature by Jean-Marc LeSieur, Managing Director, dated 10/03/2025.
Insider purchase reported: Immuneering Corp (IMRX) Chief Accounting Officer Mallory Morales reported acquiring 300 shares of Class A common stock on 10/01/2025 at a price of $6.39 per share. After the transaction, Morales beneficially owns 27,533 shares. The Form 4 was signed by an attorney-in-fact on 10/02/2025. No derivative transactions or additional remarks were reported in the filing.
Insider transaction reported for Immuneering Corp (IMRX). Leah R. Neufeld, listed as Chief People Officer and reporting person, purchased 800 shares of Class A common stock on 10/01/2025 at a price of $6.3792 per share. After the purchase, the filing reports 23,344 shares beneficially owned. The Form 4 was signed on behalf of Ms. Neufeld by an attorney-in-fact and dated 10/02/2025.
Immuneering Corp (IMRX) Chief Legal Officer and Secretary Michael D. Bookman reported a personal purchase of 1,020 shares of Class A common stock on 10/01/2025 at a price of $6.8299 per share. Following the transaction, Mr. Bookman beneficially owns 4,870 shares. The Form 4 was signed on 10/02/2025 and lists his role as an officer and director. No derivative transactions or additional remarks were reported on the filing.
Insider purchase reported by Immuneering Corp (IMRX) Peter Feinberg, identified as a Director, reported purchasing 7,500 shares of Class A Common Stock on 09/30/2025 at a weighted-average price of $7.0307 per share. After the purchase Feinberg directly beneficially owned 149,266 shares and also reported indirect holdings of 392,242 shares via PF Associates L.P., 476,615 shares via PEF LLC, and 115,441 shares via S4K Investments LLC. The filing notes the purchase was executed in multiple trades at prices from $7.0049 to $7.055. The Form 4 is signed by an attorney-in-fact on 10/01/2025.
Peter Feinberg, a director of Immuneering Corp (IMRX), reported a purchase of 5,000 Class A common shares on 09/29/2025 at a price of $7.18 per share. After the transaction he beneficially owns 141,766 shares directly, plus additional indirect holdings through entities (392,242; 476,615; 115,441), as listed on the Form 4. The filing was signed by an attorney-in-fact on 09/30/2025. This Form 4 discloses an insider purchase that increases the reporting person’s stake but contains no other financial metrics or commentary.
Immuneering Corporation (IMRX) is offering 18,959,914 shares of Class A common stock at $9.23 per share, with underwriters able to purchase up to 2,843,987 additional shares. Net proceeds from the offering and a contingent concurrent private placement with Aventis Inc., a Sanofi subsidiary, are estimated at approximately $187.4 million (about $212.0 million if the underwriters exercise their option). The company reported updated interim Phase 1/2a atebimetinib data: in 34 first-line pancreatic cancer patients dosed at 320 mg once daily with mGnP, 86% overall survival and 53% progression-free survival at nine months (median PFS 9.6 months; median OS not reached) with a median follow-up of nine months; Grade ≥3 treatment-emergent adverse events included anemia in 24% and neutropenia in 18% of patients and no Grade 5 TEAEs. Proceeds are intended to advance development and are projected to fund operations into 2029 based on current plans. The private placement of up to $25.0 million is contingent on a qualified public offering of at least $75.0 million and includes customary ownership limits and lock-up/standstill provisions.